As established diagnostic markers of AD and MCI-AD, p-tau levels were significantly elevated in both the AD and MCI-AD groups compared with the non-AD dementia and disease control groups, and Aβ42 levels were reduced in the AD and MCI-AD groups compared with the disease control group (Fig. 3c, d). This evidence concerns the gene MAPT and dementia.